New targeted therapy trial offers hope for rare, aggressive cancer
NCT ID NCT06942442
Summary
This study is testing an immunotherapy drug called tebentafusp in people with advanced clear cell sarcoma, a rare and aggressive cancer. The trial is for patients who have a specific genetic marker (HLA-A*02:01) and whose cancer cannot be removed by surgery or has spread. Participants will receive weekly tebentafusp infusions while doctors monitor their cancer with regular scans to see if the treatment slows or stops its growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HLA-A*0201 POSITIVE CELLS PRESENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Southern California - Norris Cancer Center
RECRUITINGLos Angeles, California, 90033, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.